{
    "ticker": "ORIC",
    "name": "Oric Pharmaceuticals, Inc.",
    "description": "Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer patients. Established in 2014, Oric is focused on addressing unmet medical needs in oncology by targeting critical pathways that drive tumor growth and resistance. The company\u2019s lead program is ORIC-101, a small molecule designed to inhibit the glucocorticoid receptor (GR), which is implicated in various cancers, including prostate and breast cancer. Oric's approach utilizes a precision medicine strategy, aiming to tailor treatments based on the genetic and molecular profiles of tumors. The company is also advancing additional candidates, including those targeting the immune system to enhance cancer therapies. With a robust pipeline and a commitment to scientific excellence, Oric is poised to make significant contributions to the field of oncology and improve patient outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2014",
    "website": "https://www.oricpharma.com",
    "ceo": "Doug Given",
    "social_media": {
        "twitter": "https://twitter.com/OricPharmaceuticals",
        "linkedin": "https://www.linkedin.com/company/oric-pharmaceuticals/"
    },
    "investor_relations": "https://ir.oricpharma.com",
    "key_executives": [
        {
            "name": "Doug Given",
            "position": "CEO"
        },
        {
            "name": "Harrison E. G. A. K. S. Wang",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Drugs",
            "products": [
                "ORIC-101",
                "ORIC-532"
            ]
        }
    ],
    "seo": {
        "meta_title": "Oric Pharmaceuticals, Inc. | Innovative Cancer Therapies",
        "meta_description": "Oric Pharmaceuticals is developing targeted therapies for cancer, focusing on unmet medical needs with precision medicine strategies.",
        "keywords": [
            "Oric Pharmaceuticals",
            "Cancer Therapies",
            "Biotechnology",
            "ORIC-101",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What does Oric Pharmaceuticals do?",
            "answer": "Oric Pharmaceuticals develops innovative therapies for cancer patients, focusing on precision medicine."
        },
        {
            "question": "Who is the CEO of Oric Pharmaceuticals?",
            "answer": "Doug Given is the CEO of Oric Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Oric Pharmaceuticals headquartered?",
            "answer": "Oric Pharmaceuticals is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What are Oric's main products?",
            "answer": "Oric's main products include ORIC-101 and ORIC-532, targeting critical pathways in oncology."
        },
        {
            "question": "When was Oric Pharmaceuticals founded?",
            "answer": "Oric Pharmaceuticals was founded in 2014."
        }
    ],
    "competitors": [
        "JNJ",
        "MRNA",
        "BMY",
        "AMGN"
    ],
    "related_stocks": [
        "PFE",
        "GILD",
        "ABBV",
        "REGN"
    ]
}